Open AccessPrognostic value of serum CYFRA 21‐1 and CEA for non‐small‐cell lung cancer
Author(s) -
Zhang ZhiHui,
Han YunWei,
Liang Hui,
Wang LeMin
Publication year - 2015
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.493
Subject(s) - carcinoembryonic antigen , medicine , lung cancer , hazard ratio , oncology , cytokeratin , gastroenterology , lung , cancer , confidence interval , immunohistochemistry
The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment ( CYFRA 21‐1) and carcinoembryonic antigen ( CEA ) for non‐small‐cell lung cancer ( NSCLC ) patients. Literatures related to effects of serum CYFRA 21‐1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI . Meta‐analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio ( HR ) in all NSCLC patients with high‐level serum CYFRA 21‐1 was 1.64 (95% CI 1.46–1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28–1.65, P < 0.001). Serum CYFRA 21‐1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.